4/A: 10X Fund Amends GALT Insider Sale Disclosure

An amended SEC Form 4 reveals 10X Fund, L.P., a 10% owner and director, sold 162,069 shares of Galectin Therapeutics Inc. common stock in early December 2025.

Summary

• 10X Fund, L.P., identified as a 10% owner and director of Galectin Therapeutics Inc. (GALT), filed an amended Form 4 to report changes in beneficial ownership.
• On December 2, 2025, 10X Fund, L.P. sold 30,000 shares of GALT common stock at a weighted average price of $5.47 per share.
• On December 3, 2025, an additional 132,069 shares of GALT common stock were sold at a weighted average price of $5.73 per share.
• Following these transactions, 10X Fund, L.P. directly beneficially owns 5,670,138 shares of Galectin Therapeutics Inc. common stock.
• 10X Capital Management, LLC, as the general partner of 10X Fund, L.P., and James C. Czirr, as the manager of 10X Capital Management, LLC, may be deemed indirect beneficial owners but disclaim beneficial ownership except to the extent of their pecuniary interest.

Sentiment

Score: 3

Explanation: The filing reports significant insider selling by a 10% owner and director, which is generally perceived as a negative signal regarding the company's short-term prospects or valuation.

Negatives

• Significant insider selling by a 10% owner and director, 10X Fund, L.P., totaling 162,069 shares of common stock.
• The sales occurred at weighted average prices of $5.47 and $5.73, potentially indicating that the insider viewed these price levels as opportune for selling.

Future Outlook

NA

Industry Context

NA

Related Party Transactions

• Sales of common stock by 10X Fund, L.P., a 10% owner and director of Galectin Therapeutics Inc.
• 10X Capital Management, LLC and James C. Czirr are deemed indirect beneficial owners due to their relationship with 10X Fund, L.P. and are also reporting persons in this transaction.

Stakeholder Impact

• Shareholders: May interpret the insider selling as a negative signal, potentially leading to downward pressure on the stock price due to perceived lack of confidence from a major holder.
• Management: While the filing does not provide context for the sales, significant insider selling by a director and major owner could raise questions about internal sentiment regarding the company's future.

Key Dates

Recommendation

The significant sale of 162,069 shares by a 10% owner and director, 10X Fund, L.P., suggests that a key insider may believe the stock is fully valued or that future prospects are not as strong. This insider selling typically signals a lack of confidence or a strategic decision to reduce exposure, which could lead to downward pressure on the stock price. Investors might consider reducing their holdings or avoiding new positions based on this signal.

Keywords

GALT, Galectin Therapeutics, 10X Fund, insider trading, Form 4, beneficial ownership, stock sale, director, 10% owner